Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2

3(50.0%)

Phase 3

2(33.3%)

Phase 4

1(16.7%)

6Total

Phase 2(3)

Phase 3(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02080403Phase 3Completed

The Efficacy and Safety of Chlorhexidine Gluconate Chip (PerioChip®) in Therapy of Peri-implantitis

Role: lead

NCT01079663Phase 2Completed

The Efficacy and Safety of Chlorhexidine Gluconate Chip (Periochip®) in Therapy of Symptoms in Patients With Peri-implantitis

Role: lead

NCT01211314Phase 4Terminated

Antihypertensive Efficacy of Fixed Combination Drug

Role: collaborator

NCT01249846Phase 3Completed

The Efficacy and Safety of 2.5 mg Chlorhexidine Gluconate Chip (PerioChip®) in Frequent Treatment Versus Routine Treatment in Therapy of Adult Chronic Periodontitis

Role: lead

NCT00425451Phase 2Completed

The Efficacy and Safety of PerioChip Plus (Flurbiprofen/Chlorhexidine) Formulation in the Therapy of Adult Periodontitis

Role: lead

NCT01040286Phase 2Completed

The Efficacy and Safety of Flurbiprofen Chip Versus Chlorhexidine Chip (Periochip®) in Therapy of Adult Chronic Periodontitis

Role: lead

All 6 trials loaded